Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.43
+0.0000
Post-market: 8.450.0200+0.24%19:55 EST
Volume:7.02M
Turnover:59.13M
Market Cap:758.16M
PE:-8.98
High:8.44
Open:8.42
Low:8.42
Close:8.43
Loading ...

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.
·
22 Feb

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
19 Feb

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
19 Feb

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise

MT Newswires Live
·
18 Feb

Chimerix Shares Touch 52-Week High on Speedy FDA Review of Brain Tumor Treatment

Dow Jones
·
18 Feb

Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating

MT Newswires Live
·
18 Feb

Chimerix Inc : TD Cowen Raises Target Price to $12 From $8

THOMSON REUTERS
·
18 Feb

Chimerix Inc : Wedbush Raises Target Price to $7 From $6

THOMSON REUTERS
·
18 Feb

BRIEF-Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone

Reuters
·
18 Feb

Chimerix’s NDA for dordaviprone accepted by FDA

TIPRANKS
·
18 Feb

Chimerix Inc - No Advisory Committee Meeting Planned for Chimerix's Dordaviprone Nda

THOMSON REUTERS
·
18 Feb

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27m-Mutant Diffuse Glioma

THOMSON REUTERS
·
18 Feb

Chimerix Inc - FDA Grants Priority Review to Chimerix's Dordaviprone, Pdufa Date August 18, 2025

THOMSON REUTERS
·
18 Feb

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

GlobeNewswire
·
18 Feb

Metalpha Technology Holding And 2 Other US Penny Stocks To Monitor

Simply Wall St.
·
17 Feb